All Blogs

Jun 27, 2024

Obesity, a chronic disease linked to increased risks of complications and mortality, has spurred significant research into the mechanisms of weight regulation and the gut-brain axis's role in appetite control. This understanding has paved the way for the development of safe and effective treatments, such as glucago...

Jun 27, 2024

Type 1 Diabetes (T1D) arises from the autoimmune destruction of insulin-producing islet cells in the pancreas. This destruction results in a complete loss of insulin production, leading to significant impairment in blood glucose control. Without insulin, the body cannot properly process nutrients, causing persisten...

Jun 27, 2024

Alcon's Newest Technological Marvels, Unity VCS, and Unity CS, Achieved 510(k) Clearance From the U.S. FDA, Paving the Way for New Advancements  On June 24, 2024, Alcon, the foremost name in eye care with a mission to help people see brilliantly, revealed that the U.S. Food and Drug Administration (FDA) had...

Jun 27, 2024

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications used to treat type 2 diabetes mellitus (T2DM) and obesity by lowering serum glucose levels and managing metabolism in affected patients. Companies are continuously striving to improve approved therapies and develop next-generation obesity ...

Jun 27, 2024

The American Diabetes Association (ADA), a premier voluntary health organization, has been at the forefront of combating the diabetes epidemic and enhancing the lives of individuals with diabetes for 83 years. The ADA has consistently fueled discovery and research aimed at treating, managing, and preventing diabete...

Jun 25, 2024

Triple-negative breast cancer (TNBC) constitutes about 10-15% of all breast cancer cases with nearly 44,000 incident cases in the United States in 2023, as per Delveinsight’s estimates. It is a rare but aggressive form of breast cancer. Treatment for TNBC is more limited than for other breast cancer types. C...

Jun 25, 2024

Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...

Jun 24, 2024

Quick facts The primary cause of DCM is understood to be genetic, leading to a focus on tailoring treatments based on the specific molecular origin. Genetic testing plays a crucial role in DCM, as numerous studies and case reports have demonstrated, serving as a vital tool for diagnosis, prognosis, familial scr...

Sep 24, 2024

DelveInsight forecasts that with the launch of 15+ emerging therapies alongside existing treatments, the ALS treatment market is anticipated to surpass USD 4 billion across the 7MM by 2034. Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. As per ou...

Jun 20, 2024

Boston Scientific Corporation Announced Definitive Agreement to Acquire Silk Road Medical, Inc., an Innovator in Stroke Prevention Technology On June 18, 2024, Boston Scientific Corporation, a global leader in medical technologies, announced the formal agreement to acquire Silk Medical, Inc., a medical device co...